287 related articles for article (PubMed ID: 26614901)
21. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
Imamura T; Ohtsuka E; Ogata M; Oka F; Kashima K; Kikuchi H; Nasu M
Int J Hematol; 2004 Dec; 80(5):432-4. PubMed ID: 15646655
[TBL] [Abstract][Full Text] [Related]
22. Hairy cell leukemia: a 'hair-raising' update.
Topp ZZ; Saven A
Expert Rev Hematol; 2014 Oct; 7(5):659-69. PubMed ID: 25148599
[TBL] [Abstract][Full Text] [Related]
23. Combination therapies to improve the long-term outcome in hairy cell leukemia.
Lauria F; Forconi F
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():18-22. PubMed ID: 19814693
[TBL] [Abstract][Full Text] [Related]
24. Risk of additional cancers in untreated and treated hairy cell leukemia patients.
Dasanu CA; Alexandrescu DT
Expert Opin Pharmacother; 2010 Jan; 11(1):41-50. PubMed ID: 20001428
[TBL] [Abstract][Full Text] [Related]
25. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
26. First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival.
Amhaz G; Ibrahim A; Usta U; El Cheikh J; Bazarbachi A; Abou Dalle I
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):564-566. PubMed ID: 33994319
[No Abstract] [Full Text] [Related]
27. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Saven A; Burian C; Koziol JA; Piro LD
Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
[TBL] [Abstract][Full Text] [Related]
28. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
Guest JF; Smith H; Sladkevicius E; Jackson G
Clin Ther; 2009; 31 Pt 2():2398-415. PubMed ID: 20110049
[TBL] [Abstract][Full Text] [Related]
30. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
31. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
Dearden CE; Else M; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():21-4. PubMed ID: 21599603
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
Gerrie AS; Zypchen LN; Connors JM
Blood; 2012 Mar; 119(9):1988-91. PubMed ID: 22223825
[TBL] [Abstract][Full Text] [Related]
34. Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis.
Andrasiak I; Rybka J; Wrobel T
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):392-399.e3. PubMed ID: 29685423
[TBL] [Abstract][Full Text] [Related]
35. A
Gozzetti A; Sammartano V; Bacchiarri F; Raspadori D; Bocchia M
Turk J Haematol; 2020 Nov; 37(4):286-287. PubMed ID: 32539314
[No Abstract] [Full Text] [Related]
36. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Goodman GR; Burian C; Koziol JA; Saven A
J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
[TBL] [Abstract][Full Text] [Related]
37. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
38. How I manage patients with hairy cell leukaemia.
Thompson PA; Ravandi F
Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
[TBL] [Abstract][Full Text] [Related]
39. Hairy cell leukaemia-variant: Disease features and treatment.
Matutes E; Martínez-Trillos A; Campo E
Best Pract Res Clin Haematol; 2015 Dec; 28(4):253-63. PubMed ID: 26614904
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up studies in hairy cell leukemia.
Grever MR; Zinzani PL
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():23-6. PubMed ID: 19814694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]